BridgeBio Pharma Stock Surges as Drug Impresses Investors

BridgeBio Pharma (BBIO) Stock Soars on Positive Clinical Results. Will it Last?

By:Thomas Westwater

BridgeBio Pharma Stock Surges on Positive Clinical Results

BridgeBio Pharma (BBIO), a Palo Alto biopharmaceutical company, surged 12.29% to $18.55 per share on Tuesday, extending an even more impressive 51.98% gain on Monday after announcing positive drug trial results.

The company announced positive phase 2 trial results for its candidate therapy drug infigratinib, which treats achondroplasia in children. The genetic condition causes abnormal behavior in a protein necessary for proper growth in bone within growth plate cartilage, often resulting in short-limbed dwarfism.

In the trial, ten children showed an annual gain in height velocity of about 3 centimeters. Those results are much more impressive than what is seen with Voxzogo, the only approved medication for achondroplasia, developed by BioMarin Pharmaceuticals. After BBIO’s announcement, BioMarin’s stock price fell about 7% on Monday and 0.93% on Tuesday.

Achondroplasia is the most common form of skeletal dysplasia, affecting one in every 40,000 births, according to Johns Hopkins Medicine. That makes the market for BridgeBio’s drug a rather deep one and explains the stock price’s reaction. While encouraging, the drug must progress through phase III trials, a critical step where more than half of drugs fail. That said, future road bumps with this drug would likely result in a sharp move in the other direction, but if it succeeds, more upside is expected.

Trading A Directional Bias After IV Contraction

BridgeBio Pharma saw its implied volatility rank (IVR) fall as prices rose quickly this week. That removes an incentive for premium sellers but bodes well for those wanting to take up a directional play by using calls or puts. Given the sharp increase, taking a long position may work better once a pullback occurs. Alternatively, playing a pullback in a mean-reverting strategy by using puts may be more attractive for traders now.

BBIO in trading platform

Options involve risk and are not suitable for all investors. Please read Characteristics and Risks of Standardized Options before deciding to invest in options.

Related Posts

tastylive content is created, produced, and provided solely by tastylive, Inc. (“tastylive”) and is for informational and educational purposes only. It is not, nor is it intended to be, trading or investment advice or a recommendation that any security, futures contract, digital asset, other product, transaction, or investment strategy is suitable for any person. Trading securities, futures products, and digital assets involve risk and may result in a loss greater than the original amount invested. tastylive, through its content, financial programming or otherwise, does not provide investment or financial advice or make investment recommendations. Investment information provided may not be appropriate for all investors and is provided without respect to individual investor financial sophistication, financial situation, investing time horizon or risk tolerance. tastylive is not in the business of transacting securities trades, nor does it direct client commodity accounts or give commodity trading advice tailored to any particular client’s situation or investment objectives. Supporting documentation for any claims (including claims made on behalf of options programs), comparisons, statistics, or other technical data, if applicable, will be supplied upon request. tastylive is not a licensed financial adviser, registered investment adviser, or a registered broker-dealer.  Options, futures, and futures options are not suitable for all investors.  Prior to trading securities, options, futures, or futures options, please read the applicable risk disclosures, including, but not limited to, the Characteristics and Risks of Standardized Options Disclosure and the Futures and Exchange-Traded Options Risk Disclosure found on

tastytrade, Inc. ("tastytrade”) is a registered broker-dealer and member of FINRA, NFA, and SIPC. tastytrade was previously known as tastyworks, Inc. (“tastyworks”). tastytrade offers self-directed brokerage accounts to its customers. tastytrade does not give financial or trading advice, nor does it make investment recommendations. You alone are responsible for making your investment and trading decisions and for evaluating the merits and risks associated with the use of tastytrade’s systems, services or products. tastytrade is a wholly-owned subsidiary of tastylive, Inc.

tastytrade has entered into a Marketing Agreement with tastylive (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade. tastytrade and Marketing Agent are separate entities with their own products and services. tastylive is the parent company of tastytrade.

tastycrypto is provided solely by tasty Software Solutions, LLC. tasty Software Solutions, LLC is a separate but affiliate company of tastylive, Inc. Neither tastylive nor any of its affiliates are responsible for the products or services provided by tasty Software Solutions, LLC. Cryptocurrency trading is not suitable for all investors due to the number of risks involved. The value of any cryptocurrency, including digital assets pegged to fiat currency, commodities, or any other asset, may go to zero.

© copyright 2013 - 2024 tastylive, Inc. All Rights Reserved.  Applicable portions of the Terms of Use on apply.  Reproduction, adaptation, distribution, public display, exhibition for profit, or storage in any electronic storage media in whole or in part is prohibited under penalty of law, provided that you may download tastylive’s podcasts as necessary to view for personal use. tastylive was previously known as tastytrade, Inc. tastylive is a trademark/servicemark owned by tastylive, Inc.